Salmeterol/Fluticasone
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Salmeterol/fluticasone combines an inhaled corticosteroid with a long-acting beta-2 agonist for maintenance treatment of asthma and chronic obstructive pulmonary disease. It is not a rescue inhaler, and patients should not use extra LABA therapy; the main safety concerns include serious asthma-related events with LABA monotherapy, pneumonia in COPD, oral candidiasis, adrenal suppression, bone effects, paradoxical bronchospasm, tachyarrhythmia, and hypokalemia.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Salmeterol/fluticasone combines an inhaled corticosteroid with a long-acting beta-2 agonist for maintenance treatment of asthma and chronic obstructive pulmonary disease. NutriStack rates the supporting evidence as strong. Common adult dosing is Asthma: product-specific strength, usually 1 inhalation twice daily about 12 hours apart. COPD: commonly fluticasone propionate/salmeterol 250/50 mcg inhalation powder twice daily; dosing varies by product and indication., though a prescriber sets the actual dose. This profile indexes 4 sources.
- Throat irritation
- Hoarseness
- Oral candidiasis
- Primary treatment of status asthmaticus or other acute episodes requiring intensive measures1
- Severe hypersensitivity to milk proteins for lactose-containing dry powder inhalers
The bottom line
Evidence rating strong. Most-documented uses: maintenance control of asthma in patients needing inhaled corticosteroid plus laba therapy, reduction of copd symptoms and exacerbations in appropriate patients, improved lung function and reduced rescue inhaler use. 4 sources indexed (2006–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Fluticasone activates glucocorticoid receptors in airway tissues, suppressing inflammatory cytokines, eosinophils, edema, and mucus production. Salmeterol selectively stimulates beta-2 receptors on airway smooth muscle through a long side-chain interaction, increasing cyclic AMP and producing prolonged bronchodilation. The combination addresses both inflammation and bronchoconstriction, but salmeterol must not be used without anti-inflammatory controller therapy in asthma.1,4
Dosing & protocol.
Inhaled administration is independent of meals. Rinse mouth and spit after use to reduce oral candidiasis. Use consistently twice daily and keep a short-acting rescue bronchodilator available for acute symptoms.
Full safety detail.
Side effects
- Throat irritation
- Hoarseness
- Oral candidiasis
- Headache
- Tremor
- Palpitations
- Tachycardia
- Hypokalemia at high beta-agonist exposure
- Pneumonia risk in COPD
- Adrenal suppression with high corticosteroid exposure
- Reduced bone mineral density with long-term high-dose steroid exposure
- Paradoxical bronchospasm
Contraindications
- Primary treatment of status asthmaticus or other acute episodes requiring intensive measures1
- Severe hypersensitivity to milk proteins for lactose-containing dry powder inhalers
- Known hypersensitivity to fluticasone, salmeterol, or formulation components1,4
- Do not use with another LABA2,3
- Use caution with serious cardiovascular disease, arrhythmias, seizure disorders, thyrotoxicosis, diabetes, untreated infections, or strong CYP3A4 inhibitors1,3
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseCalverley PM et al. · New England Journal of Medicine · 2007
TORCH showed effects on exacerbations and health status with an observed increase in pneumonia in corticosteroid-containing arms.
- 2The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolNelson HS et al. · Chest · 2006
SMART found increased asthma-related deaths with salmeterol added to usual care, especially when inhaled corticosteroid use was not assured.
Reviews & position papers
1- 3Global Strategy for Asthma Management and PreventionGlobal Initiative for Asthma · GINA Report · 2025
Guidelines recommend anti-inflammatory controller therapy and caution against LABA monotherapy in asthma.
Reference material
1- 4Advair Diskus US Prescribing InformationURLU.S. National Library of Medicine · DailyMed · 2026
Labeling describes indications, twice-daily dosing, LABA precautions, pneumonia, candidiasis, adrenal, bone, and hypokalemia warnings.
Common questions.
Quick answers about Salmeterol/Fluticasone, drawn from the data on this page.
What is Salmeterol/Fluticasone?
Salmeterol/fluticasone combines an inhaled corticosteroid with a long-acting beta-2 agonist for maintenance treatment of asthma and chronic obstructive pulmonary disease. It is not a rescue inhaler, and patients should not use extra LABA therapy; the main safety concerns include serious asthma-related events with LABA monotherapy, pneumonia in COPD, oral candidiasis, adrenal suppression, bone effects, paradoxical bronchospasm, tachyarrhythmia, and hypokalemia.
What is Salmeterol/Fluticasone used for?
Commonly cited benefits of Salmeterol/Fluticasone include: Maintenance control of asthma in patients needing inhaled corticosteroid plus LABA therapy; Reduction of COPD symptoms and exacerbations in appropriate patients; Improved lung function and reduced rescue inhaler use; Controller therapy for persistent airway inflammation and bronchoconstriction. NutriStack rates the overall evidence as strong.
What is a typical dose of Salmeterol/Fluticasone?
A typical adult dose of Salmeterol/Fluticasone is Asthma: product-specific strength, usually 1 inhalation twice daily about 12 hours apart. COPD: commonly fluticasone propionate/salmeterol 250/50 mcg inhalation powder twice daily; dosing varies by product and indication.. The commonly recommended form is Dry powder inhaler or metered-dose inhaler with mouth rinsing after each dose. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Salmeterol/Fluticasone?
Reported side effects include throat irritation, hoarseness, oral candidiasis, headache, tremor, palpitations. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Salmeterol/Fluticasone?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Salmeterol/Fluticasone in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.